(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) slid by a staggering 22.44% in 5 sessions from $11.58 at -22.44, to $8.98 at 15:46 EST on Thursday, after two sequential sessions in a row of gains. NASDAQ is jumping 0.55% to $11,734.66, after three successive sessions in a row of gains.
Viking Therapeutics’s last close was $9.60, 19.87% below its 52-week high of $11.98.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.67%.
Volume
Today’s last reported volume for Viking Therapeutics is 2433339 which is 1.24% above its average volume of 2262260.
Moving Average
Viking Therapeutics’s worth is below its 50-day moving average of $9.80 and way higher than its 200-day moving average of $5.08.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be overbought (>=80).
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.86%, a negative 1.33%, and a positive 3.50%.
Viking Therapeutics’s highest amplitude of average volatility was 11.28% (last week), 4.06% (last month), and 3.50% (last quarter).
More news about Viking Therapeutics (VKTX).
